Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces mortality among COVID-19 patients, but also lowers the risk of long COVID symptoms. Based on HealthVerity data from over 52,000 patients, Veklury use was linked to a 10% lower risk of conditions associated with long COVID in both people under and over the age of 65. Separate research analysed patients during the Omicron surge (Dec’21 – Apr’23), showing that immunocompromised individuals treated with Veklury had a 25% lower mortality risk compared to a control group. A final study found lower mortality rates in patients treated with Veklury in combination with dexamethasone compared to those on dexamethasone alone.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
